- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03949907
Early IntraVenous Administration of Nutritional Support (IVANS)
Early IntraVenous Administration of Nutritional Support (IVANS) in Metastatic Gastric, Cancer Patients at Nutritional Risk Undergoing First-line Chemotherapy
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Riccardo Caccialanza, MD
- Phone Number: +390382501615
- Email: r.caccialanza@smatteo.pv.it
Study Contact Backup
- Name: Emanuele Cereda, MD, PhD
- Phone Number: +390382501615
- Email: e.cereda@smatteo.pv.it
Study Locations
-
-
-
Pavia, Italy, 27100
- Recruiting
- Fondazione Irccs Policlinico San Matteo
-
Contact:
- Riccardo Caccialanza, MD
-
Principal Investigator:
- Riccardo Caccialanza, MD
-
Sub-Investigator:
- Emanuele Cereda, MD, PhD
-
Sub-Investigator:
- Paolo Pedrazzoli, MD
-
Sub-Investigator:
- Silvia Brugnatelli, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically confirmed diagnosis of metastatic gastric and gastroesophageal cancer;
- no previous chemotherapy for metastatic disease;
- indication for a first-line chemotherapy with a combination of 2 drugs including platinum derivatives (plus Trastuzumab if HER2+) to be used by investigator's choice within the framework of good clinical practice and in agreement with current Italian Association of Medical Oncology guidelines;
- measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST);
- presence of nutritional risk (Nutritional Risk Screening 2002 score ≥3);
- availability of permanent venous access (Port, Groshong, PICC);
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
- availability of a home parenteral nutrition service to continue nutritional plan as scheduled;
- signed informed consent.
Exclusion Criteria:
- age <18 years
- ECOG performance status >2
- indication to complete artificial nutrition support (totally compromised spontaneous food-intake)
- contraindication to parenteral nutrition (abnormal glucose and electrolytes control, hyper-triglyceridemia, impaired hemodynamic control and fluid retention)
- availability of jejunostomy for nutritional purposes
- ongoing home artificial nutrition
- unfeasible home parenteral nutrition for social/familial reasons
- absence of caregivers
- patients refusal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Nutritional counseling alone
Nutritional counseling consists of a personalized dietary prescription with regular consultation by a registered dietitian and telephone interviews, as well as of the use of oral nutritional supplements, when necessary.
|
Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered. In the presence of body weight loss >10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition. |
Experimental: Supplemental parenteral nutrition plus nutritional counseling
Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.
|
Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis. Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Combined endpoint - overall survival and weight maintenance
Time Frame: 12 months
|
A combined endpoint consisting of overall and/or absence of unintentional weight loss >10% of the weight recorded at enrollment
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: 12 months
|
A progression-free survival rate at 12 months will be calculated, with patients categorized in a dichotomous manner as alive and progression-free or in progression or dead at 12 months.
|
12 months
|
Overall survival
Time Frame: 12 months
|
Overall survival
|
12 months
|
Treatment-related moderate-severe adverse events as assessed by CTCAE v4.0
Time Frame: 4 months
|
Difference in the incidence of grade >=3 toxicity, according to Common Terminology Criteria for Adverse Events [CTCAE v4.0]
|
4 months
|
Eligibility to second-line chemotherapy
Time Frame: 12 months
|
The rate of patients eligible for second-line chemotherapy at 12 months will be calculated, with patients categorized in a dichotomous manner as alive and eligible or not eligible or dead at 12 months.
|
12 months
|
Total dose of chemotherapy administered
Time Frame: 4 months
|
To be calculated as the percentage of chemotherapy dose administered with respect to the treatment plan
|
4 months
|
Objective response rate
Time Frame: 4 months
|
Defined as a complete response or partial response that has been confirmed by a subsequent assessment no earlier than 2 months after the initial documentation.
Response is assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
|
4 months
|
Change in body weight
Time Frame: 12 months
|
Change in body weight during the study (at 4 and 12 months)
|
12 months
|
Change in handgrip strength
Time Frame: 12 months
|
Change in handgrip strength during the study (at 4 and 12 months)
|
12 months
|
Change in muscle mass
Time Frame: 12 months
|
Change in muscle mass during the study (at 4 and 12 months) evaluated with computed tomography scan at the level of the third lumbar vertebra
|
12 months
|
Change in phase angle
Time Frame: 12 months
|
Change in phase angle during the study (at 4 and 12 months) evaluated with bioimpedance vectorial analysis
|
12 months
|
Patients requiring unplanned hospitalization
Time Frame: 12 months
|
The rate of patients requiring unplanned hospitalization (one or more) at 12 months will be calculated.
|
12 months
|
Change in self-perceived quality of life
Time Frame: 12 months
|
Change in self-perceived quality of life during the study (at 4 and 12 months) as assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 [EORTC QLQ-C30]
|
12 months
|
Incidence of infections
Time Frame: 12 months
|
The rate of incident infections in each group and the related difference will be calculated
|
12 months
|
Abnormal values in safety laboratory variables
Time Frame: 12 months
|
The number of participants with abnormal values in safety laboratory variables will be calculated and compared between groups
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum levels of immunologic profiles
Time Frame: 1 months
|
Levels of soluble effectors and immunoregulatory cells at 1 week and 1 month from the start of chemotherapy
|
1 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emanuele Cereda, MD, PhD, Fondazione Irccs Policlinico San Matteo
- Study Chair: Riccardo Caccialanza, MD, Fondazione Irccs Policlinico San Matteo
- Study Director: Paolo Pedrazzoli, MD, Fondazione Irccs Policlinico San Matteo
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20190028466
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of Stomach
-
Chinese University of Hong KongRecruiting
-
ASLAN PharmaceuticalsCompletedStomach Neoplasms | Gastric Cancer | Gastric Neoplasms | Cancer of Stomach | Cancer of the StomachKorea, Republic of
-
Enzon Pharmaceuticals, Inc.TerminatedCancer of Stomach | Gastroesophageal Cancer
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IV Gastric Cancer | Recurrent Gastric Cancer | Stage III Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the StomachUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); ECOG-ACRIN Cancer Research GroupWithdrawnGastrointestinal Cancer | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Adenocarcinoma of the Esophagus | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric... and other conditionsUnited States
Clinical Trials on Nutritional counseling alone
-
Charite University, Berlin, GermanyCompletedIBS - Irritable Bowel SyndromeGermany
-
Hospital de Clinicas de Porto AlegreActive, not recruitingBinge-Eating Disorder | Cognitive Behavioral Therapy | Transcranial Direct Current StimulationBrazil
-
University of PadovaFondazione Guido Berlucchi; Veneto Institute of Oncology I.O.V.-I.R.C.C.S.Terminated
-
William Carey UniversityUniversity of Mississippi Medical Center; University of Southern MississippiCompletedSpinal Cord InjuriesUnited States
-
Société des Produits Nestlé (SPN)CompletedPicky Eating BehaviorsChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCancer SurvivorUnited States
-
Vestre Viken Hospital TrustUniversity of OsloRecruitingCardiovascular Diseases | Schizophrenia | Bipolar Disorder | PsychosisNorway
-
Institut de Recherches Cliniques de MontrealCompletedMetabolic Syndrome | Type 1 DiabetesCanada
-
Abington Memorial HospitalUnknownObesity | PregnancyUnited States